Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | CA4 | P22748 | 4/20 | 0.47 |
| ▸ | CA6 | P23280 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11794283 | 0.98 | PTGS2 (0.51) | PTGS2PTGS1OPRK1HTTKMT2A | |
| SCHEMBL9166295 | 0.96 | PTGS2 (0.56) | PTGS2PTGS1OPRK1HTTKMT2A | |
| SCHEMBL9790769 | 0.84 | PTGS2 (0.57) | PTGS2PTGS1OPRK1HTTKMT2A | |
| SCHEMBL4595 | 0.84 | PTGS2 (0.57) | PTGS2PTGS1OPRK1HTTKMT2A | |
| SCHEMBL29169546 | 0.84 | PTGS2 (0.57) | PTGS2PTGS1OPRK1HTTKMT2A | |
| SCHEMBL7623394 | 0.82 | NPC1 (0.57) | PTGS2PTGS1OPRK1HTTKMT2A | |
| SCHEMBL9147334 | 0.82 | PTGS1 (0.52) | PTGS2PTGS1OPRK1HTTKMT2A | |
| SCHEMBL225031 | 0.82 | PTGS2 (0.56) | PTGS2PTGS1OPRK1HTTKMT2A | |
| SCHEMBL7338783 | 0.82 | PTGS2 (0.56) | PTGS2PTGS1OPRK1HTTKMT2A | |
| SCHEMBL6387863 | 0.82 | PTGS1 (0.52) | PTGS2PTGS1OPRK1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| EP-1716100-A2 | THERAPEUTIC AMIDE DERIVATIVES | Pfizer, Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| US-7126010-B2 | Benzylcycloalkyl amines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| WO-2005080317-A2 | THERAPEUTIC AMIDE DERIVATIVES | PFIZER JAPAN, INC. (JP) | 2005-09-01 | — | — | WO | disclosed |
| US-20050124671-A1 | Benzylcycloalkyl amines as modulators of chemokine receptor activity | WACKER DEAN A (US) | 2005-06-09 | — | — | US | disclosed |
| US-6864380-B2 | Benzylcycloalkyl amines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-03-08 | — | — | US | disclosed |
| US-20040014758-A1 | Benzylcycloalkyl amines as modulators of chemokine receptor activity | WACKER DEAN A (US) | 2004-01-22 | — | — | US | disclosed |
| US-6608227-B1 | Prevention of inflammatory diseases such as asthma and other allergic diseases | BRISTOL-MYERS SQUIBB PHARMA | 2003-08-19 | — | — | US | disclosed |
| EP-1220836-A2 | BENZYLCYCLOALKYL AMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Pharma Company (US) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001028987-A1 | BENZYLCYCLOALKYL AMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | GRIN1, GRIN2B, GRIN3A | PTGS2 998/4885PTGS1 641/4885OPRK1 101/4885 |
| US-20040014758-A1 | Benzylcycloalkyl amines as modulators of chemokine receptor activity | CCR3, CCR1, CCR10 | PTGS2 1471/4885PTGS1 466/4885OPRK1 173/4885 |
| US-20050124671-A1 | Benzylcycloalkyl amines as modulators of chemokine receptor activity | CCR3, CCR1, CCR10 | PTGS2 1133/4885PTGS1 556/4885OPRK1 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.